Tango Therapeutics Appoints Finance Leader Sung Lee To Board As Company Prepares Vopimetostat For Registrational Studies

Tango Therapeutics, Inc., a clinical-stage biotechnology company focused on developing the next generation of precision cancer medicines, has announced the appointment of Sung Lee to its Board of Directors. Mr. Lee brings more than two decades of finance leadership experience across the biopharmaceutical and technology sectors.

Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics, said the company is pleased to welcome Mr. Lee to the Board, noting that his expertise in corporate strategy, investor relations, and financial management will be valuable as Tango advances its lead program, vopimetostat, into registrational studies. She added that his experience will also support the company’s efforts to expand and strengthen its organization as it progresses further into late-stage clinical development.

Sung Lee currently serves as Executive Vice President and Chief Financial Officer at Cytokinetics, a position he assumed in May 2024. Before joining Cytokinetics, he held Chief Financial Officer roles at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics, contributing to strategic planning and organizational growth at each company. Earlier in his career, he spent 14 years at Gilead Sciences, where he held several senior roles, including Senior Vice President of Financial Planning and Analysis and Head of Investor Relations. His work at Gilead broadened his leadership experience and strengthened his expertise across key financial functions. 

Mr. Lee began his career in the tax advisory division at PwC, where he gained foundational experience in finance and taxation. He holds a bachelor’s degree in economics from the University of California, Irvine, and a Master of Business Taxation from the University of Southern California. His appointment to Tango Therapeutics’ Board of Directors reflects the company’s commitment to strengthening its leadership team as it advances its precision oncology pipeline and prepares for future development milestones.